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Abstract
Hepatocellular carcinoma (HCC) has been a major health problem in Egypt
with extensive eorts and studies done in enhancing chemotherapeutic drugs for
more optimal results. Existing chemotherapeutic drugs are costly with problem-
atic side eects. Recent studies have demonstrated the anticancer potential of
antihistamines on dierent types of cancer, including HCC. Antihistamines have
been proven to induce cell cycle arrest and/or apoptosis through dierent mech-
anisms depending on their role on dierent cancer types. The second generation
antihistamine, loratadine (LOR), was found to have tumor inhibiting eects on
human colon carcinoma cell line. However, no studies were done neither on the in-
uence of loratadine on HCC cells, nor the eect of the combination of loratadine
with existing chemotherapeutic drugs to test its potential to improve chemother-
apy. Here, the cytotoxic potential of loratadine and the combination of loratadine
and cisplatin on HepG2 and SNU449 were investigated. Cell viability assay was
performed to show that there is a dose-dependent cytotoxic eect of LOR on both
HCC cell lines and that there is a synergistic to additive eects when LOR was
introduced to the cells in combination with cisplatin when the IC50 of both drugs
were used. Loratadine did not show a cytotoxic eect on normal cells when used
in low concentrations (<55.6 M). However, when used in higher concentration
(<73.2 M), LOR showed a high cytotoxic eect. Apoptotic and cell cycle anal-
ysis showed that loratadine induced apoptosis and cell cycle arrest in the G2/M
phase in SNU449 cells, while combination of loratadine and cisplatin may induce
necrosis and cell cycle arrest in G2/M phase. Taken together, loratadine oers a
strong basis to be further developed either alone or in combination with cisplatin
as a treatment option for advanced hepatocellular carcinoma. Further studies are
required to test the eect of loratadine treatment in vivo and perhaps to test
the eect of loratadine in combination with sorafenib in vitro and in vivo for the
hope to improve HCC therapy.
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Introduction 1
Introduction
Cancer became an immense burden worldwide as it's a multifactorial disease.
Cancer represents the second main cause of deaths in the world, around 13% of
all global deaths [1]. Ways to enhance the diagnosis and/or treatment of cancer
has become the highlight of research, as current tools, methods and therapies are
still not sucient to decrease incidence rates. Generally, the available ways for
cancer treatment include surgery, chemotherapy and radiotherapy, which showed
an increase in the patient's survival rates of some cancer types. However, such
treatments are known to cause life threatening side eects, leaving cancer patients
agitated and unsatised. Therefore, targeted therapies in which drugs are aimed
to target certain proteins and genes that are responsible of cancer growth, can
oer a way to improve cancer treatment [1]. Examples of the success of targeted
therapies in chemotherapy includes sorafenib for advanced hepatocellular carci-
noma (HCC), trastuzumab for breast cancer, bevacizumab for colon cancer, and
erlotinib for lung cancer [2].
In Egypt, liver (33.6%) and bladder (10.7%) cancer ranks highest among males
while breast (32%) and liver (13.5%) cancer ranks highest among females in Egypt
[3]. HCC has become a huge burden in the Egyptian population due to the fact
that patients get diagnosed in the advanced stages, where the liver is already
cirrhotic. Numerous research studies have been conducted to decrease incidence
rates by developing more sensitive, non-invasive methods and techniques to di-
agnose HCC such as molecular biomarkers [4], and to increase survival rates by
developing more targeted therapies to improve chemotherapy, which is the only
treatment option for advanced HCC (see Figure 1.2).
Antihistamines have been showing anticancer potential for the past 20 years,
where terfenadine, a second generation antihistamine, was rst to record sensitiz-
ing human breast cancer cells and murine leukemia cells to a chemotherapeutic
drug called doxorubicin and therefore restoring sensitivity to resistant cells in
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1993 [5]. This allowed looking into the possibility of using antihistamines in
chemotherapy as anticancer drugs or to improve the eectiveness of chemother-
apy by sensitizing resistant cells to chemotherapeutic drugs or simply causing
cell death with minimal side eects, compared to chemotherapeutic drugs used
alone. [5, 6, 7]. An advantage of using antihistamines in chemotherapy may lie in
the fact that second generation antihistamines had already been through clinical
trial phases and therefore is known to be safe with minimal side eects [8] and
this could be very benecial in chemotherapy, as chemotherapy is known to cause
serious side eects. Therefore, using already clinically investigated drugs with an
anticancer potential oers an advantage in chemotherapy to decrease the severe
side eects of chemotherapy.
The aim of this study is to rst evaluate the potential of the second generation
antihistamine loratadine (LOR) to be used as an anticancer drug by testing its
eect individually on HCC cell lines and second, to test the eect of LOR in
combination with the known and thoroughly studied chemotherapeutic agent,
cisplatin (CisPt) to test the hypothesis of improving chemotherapy. The nal
aim is to investigate whether LOR and its combination with CisPt will induce
apoptosis or necrosis, and whether it will induce cell cycle arrest.
Literature Review 3
Chapter 1
Literature Review
1.1 Hepatocellular Carcinoma
1.1.1 Epidemiology and Etiology
Hepatocellular carcinoma is the sixth most common cancer [9, 10] and is known
to be the third main cause of cancer deaths worldwide [11, 10]. It is the rst
and second most common cancer in males and females in Egypt, respectively
[3, 10].The incident rate of HCC in Egypt doubled since 2005 and became a burden
in the Egyptian population because of its asymptomatic nature in its early stages
[11, 7]. As shown in Figure 1.1, hepatitis patients are known to have higher risks
of developing HCC, owing to the high and increasing prevalence of HCV in Egypt.
Smoking, diabetes mellitus, obesity, alcohol and food contaminated with aatoxin
are also known risk factors of HCC, as demonstrated in Figure 1.5 [11, 12].
1.1.2 Diagnosis and Treatment
The asymptomatic nature of HCC makes it very dicult to be diagnosed. Ac-
cording to Feng et al (2015), 85% of HCC patients are diagnosed in the intermedi-
ate and advanced stages [7]. HCV patients or patients with cirrhotic liver, called
high risk patients, are usually screened and assessed every 4 months for early
detection to undergo liver transplantation once diagnosed with HCC. According
to ESLC [14], a patient is diagnosed with HCC if: the tumor size is bigger than
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Figure 1.1: Stages of HCC development. Adapted from Thornton, 2015. Figure
was reused with permission from Reference [13], see appendix 1
1 cm and the serum alpha fetoprotein, a known HCC marker, is higher than 200
ng/ml, in addition to a triple phase computed tomography (CT) scan to evaluate
the liver lesion. MRI (Magnetic resonance imaging) and liver biopsy may also be
required for HCC diagnosis [4].
Treatment is given based on the tumor stage, patient's performance grade and
the status of the liver, whether it's functional or not [4, 14]. Figure 1.2 shows the
staging of HCC based on the Barcelona Clinic of Liver Cancer (BCLC) staging
system and the treatment options for every stage. Child-Pugh is a system used
to assess the status of the liver in cirrhotic patients. For early staging, in which
a single tumor of a size less than 2 cm or at most 3 nodules with sizes less than 3
cm is present, treatment options include resection if the patient has a normal por-
tal pressure and bilirubin, liver transplantation if the patient has elevated portal
pressure and bilirubin, and if the patient has elevated portal pressure and biliru-
bin and developed a disease due to the elevation, either percutaneous ethanol
injection: use of a needle directed by CT to inject ethanol in the tumor, causing
dehydration and protein dehydration or radiofrequency ablation: use of electro-
magnetic energy to injure the tumor thermally [15] is used. For intermediate
stages, where multinodular with sizes larger than 3 cm are present, chemoem-
bolization or TACE (trans-arterial chemoembolization) is used for treatment, in
which the chemotherapeutic drug is combined with beads that blocks the blood
ow to the tumor, leading to the inhibition of tumor growth. This mixture is then
directly injected to the tumor site in the liver, directed by CT, which allows the
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treatment to be targeted only to the tumor site [16]. For advanced stages where
metastasis begins to take place and the tumor invades the portal vein, chemother-
apy using sorafenib, a tyrosine kinase inhibitor which inhibits tumor proliferation
and angiogenesis [17] and other multikinase inhibitors are used. As for end stage
or terminal HCC, the liver loses its ability to function and the patient's sur-
vival rate decreases tremendously. At this point, only medical treatments of the
symptoms can be administered [4, 14, 2].
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Figure 1.2: BCLC staging system for HCC and available treatment options. PS:
Performance Status. N1: one cancerous lymph node. M1: Metastasis.
PEI/RF: Percutaneous ethanol injection/ Radiofrequency. Adapted
from Llovet et al, 2008. Figure was reused with permission from
Reference [2], see appendix 2
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Given the fact that most HCC cases are diagnosed in the intermediate or ad-
vanced stages, immediate treatment is needed. The most eective treatment in
these stages is chemotherapy. Even though sorafenib is widely used in chemother-
apy for advanced stages, cisplatin is considered one of oldest and most thoroughly
studied chemotherapeutic agent. Ciplatin is a platinium based drug that is ab-
sorbed highest in the liver, prostate and kidney, and exists in tissues for about
180 days and is eleminated in urine. Cisplatin, (Figure 1.3) is one of the known
chemotherapeutic agents used to treat multiple malignant tumors including liver
cancer [18]. As presented in Figure 1.4, cisplatin is known to induce apoptosis
by forming bifunctional adducts leading to DNA damage leading to apoptosis
through several dierent pathways [19]. Cisplatin activates the cell cycle check-
points (Chk) and cause a temporary arrest in the S-phase leading to the inac-
tivation of Cdc-2 cyclin A or B kinase in order to cause cell cycle arrest in the
G2/M phase. In later events, increased amount of cells gets accumulated in the
G1 phase and gets trapped in the G2/M phase as a result of the inactivation of G1
phase CDKs (Cyclin dependent kinases) caused by cisplatin. Moreover, cisplatin
aects the p53 (ATR and CHK1) and MAPK pathways, as well as intrinsic (Bax,
casp-9, cyt c) and extrinsic apoptotic pathways (casp-8) [20].
Figure 1.3: Chemical Formula of Cisplatin [21]
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Figure 1.4: Overview of the dierent pathways and proteins aected by Cisplatin.
Adapted from Siddik, 2003. Figure was reused with permission from
Reference [20], see appendix 3
Chemotherapy using a combination of anticancer drugs for the purpose of tar-
geting multiple pathways at once is common, especially for cancers like hepato-
cellular carcinoma which is one of the most chemo resistant tumors [4] as HCC
cells carry high load of genetic mutations [22]. In fact, a combination of cisplatin,
doxorubicin, 5-orouracil, and interferon alpha, abbreviated PIAF passed phase
II study for advanced hepatocellular carcinoma with a median overall survival of
8.9 months. The one disadvantage of such treatments is the severe side eects it
introduces to the patients, such as hematological toxicity and signicant mylo-
suppression [23]. Therefore, ways to improve chemotherapy are highly required,
as it is the only treatment option available for patients suering from advanced
hepatocellular carcinoma.
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1.1.3 Molecular Pathogenesis of HCC
As illustrated in Figure 1.5, HCC has an extensive display of genetic changes,
such as chromosomal deletions or amplications and somatic mutations, and epi-
genetic changes, such as histone modications, upregulation or downregulation of
microRNAs and long noncoding RNAs, and chromatin remodeling, making it a
very complex and heterogeneous type of cancer.
There are multiple signaling pathways that are known to be dysregulated in
HCC. One of these pathways is the WNT/ -catenin or canonical Wnt signaling
pathway. The activation of this pathway results from the binding of WNT ligands
to frizzled receptors, which causes -catenin to accumulate in the cytoplasm and
gets transferred in the nucleus where it controls certain oncogenes, such as c-myc,
cyclin D and survivin [12, 2].
The activation of another important pathway that plays a role in HCC (50%
of the cases) is the receptor tyrosine kinase pathway. The activation of this
pathway via the binding of ligands to dierent growth factor receptors (GFR),
such as EGFR (epidermal), FGFR (broblast), HGFR (hepatocyte), and VEGFR
(vascular endothelial), IGFR (insulin), leading to its phosphorylation and there-
fore the activation of downstream targets: MAPK and PI3K-Akt pathways.
The activation of the MAPK pathway or mitogen activated protein kinase
(Ras/Raf/MEK/ERK) activates proto-oncogenes and transcriptional factors that
cause the transcription of genes responsible of cell dierentiation. On the other
hand, the PI3K-Akt pathway or phosphatidylinositol 3 kinase-protein kinase B,
activation either through (a) IGFR which stimulates carcinogenesis by damaging
the mammalian target of rapamycin or mTOR protein, which acts as a controller
of cell proliferation , or (b) mutations or epigenetic changes that causes loss of
function of PTEN, a tumor suppressor gene [12, 2].
Apoptotic pathways are also known to be escaped in cancer. Extrinsic and
intrinsic pathways are the two main pathways of apoptosis. The extrinsic signal-
ing pathway is initiated by the binding of homologous trimeric ligands to death
receptors, which recruits a cascade of proteins forming a death-inducing signal-
ing complex or DISC leading to the activation of pro-caspase 8 and caspase 8,
triggering apoptosis. The intrinsic signaling pathway involves intracellular or mi-
tochondrial signaling, in which an opening in the inner mitochondrial membrane
results in cytochrome c release from the intermembrane space of the mitochondria
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Figure 1.5: Pathogenesis of HCC. Adapted from Dhanasekaran et al, 2016. Figure
was reused with permission from Reference [12], see appendix 4
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to the cytosol. Cytochrome C then binds to Apaf-1 and pro-caspase 9, activating
both, forming an apoptosome. This cause caspase 9 activation, which triggers
apoptosis [24, 2].
Other pathways that have been reported to be activated in HCC include trans-
forming growth factor-beta (TGF) pathway, JAK/STAT pathway, and ubiquitin
proteasome pathway [12].
1.2 Antihistamines
1.2.1 Background
Antihistaminic drugs are well known for treating dierent types of allergies.
Generally, such drugs target histamines by binding to and blocking histamine
receptors: H1 receptor, found in stomach, intestine, bladder, H2 receptors, found
in gastric cells, H3 receptors, found in the central nervous system and H4 recep-
tors, found in immune cells, altering the histamine's action. Antihistamines are
categorized into rst generation and second generation drugs. First generation
antihistamines, such as cyproheptadine, carbinoxamine and clemastine, are se-
dating, cause cognitive impairment, cause CNS (central nervous system) eects,
and are not fully and optimally clinically investigated, as such drugs were pro-
duced before clinical trials were required. On the other hand, second generation
antihistamines, such as astemizole, loratadine and terfenadine, are nonsedating,
cause no impairment, have minimal CNS eects, and are meticulously studied
and examined in clinical trials [8].
As histamine is documented to favor cell proliferation and dierentiation and
tumor progression via H1 receptor, antihistamines are hypothesized to induce cell
death [8, 25, 26]. Even though histamines usually act by binding to H1 receptors,
H2, H3, and h4 receptors
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1.2.2 Antihistamine's Role in Cancer
1.2.2.1 Astemizole
Astemizole, an old second generation antihistaminic drug, was discovered in
2011 to decrease tumor proliferation in vitro and in vivo by targeting and in-
hibiting Eag1: an essential protein required in cancer progression [27]. In 2015,
Chavez-Lopez et al [28] continued to study the eect of astemizole in HCC cells
and found that Eag1 expression is elevated in human HCC and astemizole inhib-
ited proliferation of HCC cells and induced apoptosis in 2 HCC cell lines: HepG2
and HuH-7, by blocking and inactivating the Eag1 channels, as shown in Figure
1.6. Moreover, astemizole caused the protein Eag1 perinuclear localization from
the cytoplasm, which was observed in other cancer types, such as breast cancer
[28].
Figure 1.6: Proposed eect of Astemizole on HCC. Adapted from Chavez-Lopez
et al, 2016. Figure was reused with permission from Reference [4], see
appendix 5
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1.2.2.2 Cyproheptadine Hydrochloride
Cyproheptadine, a rst generation antihistamine, was discovered accidently in
2012, by Feng and his group, to achieve total tumor remission when taken with
thalidomide in HCC patients with lung metastasis [29], who took cyproheptadine
for skin itching. The same group investigated the eect of cyproheptadine on the
HCC cell lines, HepG2 and HuH-7, and in 2015 concluded that cyproheptadine
suppressed proliferation of HCC cells by inducing cell cycle arrest. The proposed
drug's mechanism of action, based on their study, was through the activation of
p38 MAPK facilitating the stimulation of cell regulatory proteins, resulting in cell
cycle arrest in both cell lines: G1 phase in HepG2 and G1/S transition in Huh-7,
along with apoptosis induction in HuH-7 cell lines, as shown in Figure 1.7 [7].
Figure 1.7: Proposed mechanism of cyproheptadine (CPH) action on HCC cell
lines. Adapted from Feng et al, 2015. Figure was reused with permis-
sion from Reference [7], see appendix 6
1.2.2.3 Terfenadine
Terfenadine, a second generation antihistamine, is known for its lack of CNS
side eects and therefore is widely studied over the years for its anticancer ef-
fect on a number of cancer cell lines, including Hepatocellular carcinoma HepG2,
colon cancer cells COLO 205, colorectal adenocarcinoma HT29 and broblasts
CCD 922SK [30] via G0/G1 cell cycle arrest and apoptosis through cytochrome
p450 3A4 (CYP 3A4) inhibition. In addition, melanoma A375 cells was studied
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by Jangi et al in 2008 then in 2011 [31], which concluded that terfenadine in-
duced apoptosis and autophagy through dierent signaling pathways. Moreover,
terfenadine was discovered by Wang and his group in 2014 to induce apoptosis
in 2 prostate cancer (HRPC) cell lines: PC-3 and DU-145, via the breakage of
the induced myeloid leukemia cell dierentiation (Mcl-1) protein which further
activated the overexpression of Bak (Bcl-2 homologous antagonist killer protein)
leading to the cytochrome C release from the mitochondria and therefore inducing
DNA damage and apoptosis. Finally, terfenadine was found to have a synergistic
eect when combined with epirubcin to prevent the proliferation of non-small cell
lung cancer (NSCLC) and stop resistant cells from metastasis both in vitro and
in vivo [32].
1.2.2.4 Loratadine
Loratadine (Figure 1.8) is a second generation antihistamine and according
to the FDA (Food and Drug Administration), it is absorbed quickly following
oral administration of 10mg and and the pharmacokinetics of LOR is not dose-
dependent over the dose range from 10mg to 40mg. Moreover, 80% of LOR
administered is equally disperesed in urine and feces. LOR is metabolized by
cytochrome P450 3A4 (CYP3A4) to descarboethoxyloratadine. LOR was rst
found to inhibit cell proliferation of human colon cancer (COLO 205) cells in
2006 by Chen and his group, who performed an intensive research that included
in vitro and in vivo experiments on LOR eect on COLO 205 cells. They are the
rst to report that LOR induced cell cycle arrest in G2/M phase by 3 dierent
mechanisms: (1) the upregulation of checkpoint kinase 1 (Chk1), (2) the downreg-
ulation of cell division cycle 25C (CDC25C), and (3) inactivation of BAD protein,
which is a pro-apoptotic protein, resulting in caspase 9 mediated apoptosis [6].
LOR was further studied from another angle in cancer treatment in 2010 by Soule
et al based on the ndings of Chen et al in 2006. They hypothesized that since
G2/M phase is a radiation sensitive phase, maybe LOR has an eect on the radio
sensitivity of human colon carcinoma (HT29) cells. After studying the eect of
radiation on LOR-treated cells, cell cycle phase by ow cytometry and study-
ing the expression of cell regulatory proteins by western blot, they established
the results that cells pre-treated with LOR did signicantly increase radiation
induction of cytotoxicity and that it directly induces DNA damage. They nally
concluded that LOR is not only a successful chemotherapeutic agent but also a
\modier of radiation responsiveness in the treatment of cancer" [33].
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Figure 1.8: Chemical Structure of Loratadine [34]
1.2.2.5 Others
An intensive recent study by Ellegaard et al (2016) was conducted to screen the
eect of multiple antihistamines, including astemizole, terfenadine, loratadine,
desloratadine, ebastine and clemastine, on NSCLC. After cytotoxicity experi-
ments on all the mentioned antihistamines, loratadine and astemizole was found
to decrease cancer mortality. They then implemented a study testing the eect of
those antihistamines on NSCLC, breast, and prostate cancer patients and found
that low concentrations of loratadine, astemizole and ebastine cause NSCLC sen-
sitized to chemotherapy and regressed multidrug resistance in all cancer types
[35].
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1.3 Hypothesis and Objectives
Given all the mentioned data from research within the past 15 years, one can
propose that antihistamines does have an anticancer eect on several dierent
cancer cell lines, including HCC cell lines and could strongly improve chemother-
apy.
Even though LOR was thoroughly studied on human colon cancer cells, no
studies have been attempted to test the eect of loratadine on HCC cell lines.
Moreover, no research was conducted to investigate the combination eect of LOR
and CisPt on HCC cell lines.
Therefore, the research hypothesis is that LOR will inhibit the proliferation
of HCC cells and there will be a synergetic or an additive eect when LOR is
combined with cisplatin. In order to test this hypothesis, the objectives of this
study is to
1. Determine the cytotoxic eect of LOR against 2 HCC cell lines: HepG2,
originated from a 15 year old Caucasian male with pure liver carcinoma cell
line (absence of viral infection) [36, 37] and SNU449, originated from a 52
year old Asian male with grade II-III/IV hepatocellular carcinoma cell line
containing hepatitis B virus [38, 39], by cell viability assay.
2. Identify the combination eect of LOR and cisplatin on HepG2 and SNU449
by cell viability assay followed by combination analysis using median eect
analysis proposed by Chou and Talalay (2006).
3. Detect if LOR and the combination of LOR and cisplatin will induce early
apoptosis or necrosis by annexin V and propidium iodide staining.
4. Examine the eect of LOR and the combination of LOR and cisplatin on
the cell cycle in SNU449 cells by ow cytometry.
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Chapter 2
Materials and Methods
2.1 Cell Culture
Human HCC cell lines HepG2 and SNU449 (provided by Dr. Mehmet Oz-
turk from the Department of Molecular Biology and Genetics, Bilkent University,
Turkey) were cultured in RPMI 1640 (Lonza, USA) supplemented with 10% heat-
inactivated fetal bovine serum (Invitrogen, USA) and 5% penicillin-streptomycin
antibiotic (Invitrogen, USA). Cells were incubated at 37C in a humidied atmo-
sphere of 5% CO2.
2.2 Preparation of Drugs
According to Feng et al (2015) [7], Loratadine (LOR), purchased from
Hangzhou Dayangchem Co., Limited, China, was dissolved in dimethyl sulfox-
ide or DMSO at a concentration of 100mM, which was then diluted with RPMI
media to prepare concentrations of: 0.1 M, 0.3 M, 1 M, 3 M, 10 M, 30
M4, 100 M, and 300 M.
Cisplatin (CisPt), MYLAN 10mg, was diluted with RPMI media to prepare
concentrations of 0.1 M, 0.3 M, 1 M, 3 M, 10 M, 30 M, 100 M, 300 M
and 1000 M.
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2.3 Cell Viability Assay
MTT or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide has been
widely used to determine cell viability and identify cytotoxicity of drugs. It is
a positively charged tetrazolium salt which is able to penetrate the eukaryotic
cell easily. When MTT is added to cells and incubated for approximately 4
hours, viable cells with active mitochondrial enzymes are able to convert MTT
to formazan, a purple colored product, which is accumulated inside the cell as
a precipitate, after which DMSO is added to solubilize the formazan product,
allowing the measurement of the absorbance of the color by a plate reader at a
wavelength of 570nm. Dead cells however, lose their ability to convert MTT to
formazan, as they lack the mitochondrial enzymes responsible of the conversion
[40].
HepG2 and SNU449 cells were seeded in 96 well plates (Greiner Bio-One, Ger-
many) at 10,000 cells per well and cultured for 24 hrs. The cells were treated
with the dierent concentrations of LOR and CisPt, mentioned in the previ-
ous section, for 24 hrs, using untreated cells as a control. MTT (SERVA Elec-
trophoresis, Germany) was added to the cells and incubated for 3 hrs in the
dark. DMSO was then added to the cells, plates were shaken for 5 min then the
SPECTROstar Nano Microplate Reader, BMG LABTECH, was used to mea-
sure the optical density at 570nm. Untreated cells that were used as controls,
signied 100% cell viability. A dose-dependent graph was conducted by Graph-
Pad Prism 5.0 software (GraphPad Software, La Jolla, CA) plotting cell viability
vs. drug concentration, after which the IC50 or the drug concentration that
caused 50% cell death was then calculated for each cell line using the equation:
Y = Bottom+(Top Bottom)=(1+10((X LogIC50))), where X is the log of the dose
or concentration; Y is the response, decreases as X increases; Top and Bottom is
the plateaus in same units as Y, and logIC50 is the same log units as X.
2.4 Drug Combination Index
Combination of drugs is a common concept in chemotherapy, where the synergy
of dierent strong anticancer drugs are used to attack the cancer cells vigorously
and also as a solution to drug resistance. Chou and Talalay (2006) proposed
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Table 2.1: Drug Combinational Experimental Design.
an eective method for the evaluation of drug combinations quantitatively using
a median eect analysis [41]. In order to determine whether the combination
eect of the two drugs is synergistic, additive, or antagonistic, the experiment
was prepared as follows: for each cell line, the IC50 of each drug individually was
calculated, after which a serial dilution was prepared for each drug and combined
together with a constant ratio, as illustrated in Table 2.1.
HepG2 and SNU449 cells were seeded in 96 well plates at 10,000 cells per well
and cultured for 24 hrs. The cells were treated with LOR, CisPt, and the 5
dierent combinations, as shown in Table 2.1, for 24 hrs, using untreated cells
as a control. MTT was added to the cells and incubated for 3 hrs after which
DMSO was added to the wells, plates were shaken for 5 min then the optical
density was measured at 570nm using a SPECTROstar Nano Microplate Reader,
BMG LABTECH.
CompuSyn software (Paramus, NJ) was used to calculate the combination index
or CI, according to the median eect principle of Chou and Talalay, to determine
whether the eect of the combination is synergistic, additive or antagonistic.
2.5 Cytotoxicity of LOR, CisPt, and Combination
IC50 on Normal Cells
To evaluate the cytotoxicity of the IC50 of LOR and CisPt, and Combination
IC50 on normal cells, 1 Br hTERT- human immortalized skin broblasts (gifted
from Dr. Andreas Kakarougkas, University of Sussex, UK) was used as a control
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cell line for MTT cell viability assay, as described above. 1 Br hTERT was used
in multiple studies as normal cells to compare the eect of certain drugs between
cancer and normal cells [42], [43], [44]. Immortalized cells oers the advantage of
proliferating in culture and therefore is easier to use than primary cultures.
2.6 Annexin V Apoptotic Assay
Phosphatidylserine (PS) is a phospholipid that is located in the inner membrane
of the cell. During early stages of apoptosis, PS gets translocated to the outer
membrane of the cell and is considered to be a hallmark of apoptosis. Annexin
V is a known PS-binding protein that is used to track apoptosis [24].
RotitestR Annexin V kit (Carl Roth, Germany) uses the binding eciency
of annexin V to PS to label damaged cells and also uses propidium iodide to
counterstain the nuclei of cells with opened membranes, which is an indication
of necrosis. This gives an advantage of not only tracking apoptosis, but also for
distinguishing apoptosis from necrosis.
SNU449 cells were cultured in 6 well plates at a density of 500,000 cells per well
for 24 hrs. Cells were treated with: IC50 of LOR, IC50 of CisPt, and Combination
IC50 in FBS-free media, for 24 hrs with untreated cells as controls. According
to the manufacturer's instructions, a single cell suspensions were prepared by
trypsinization and washed with PBS twice. Annexin V binding buer was diluted
(10-folds) and added to the cells, after which Annexin V-FITC conjugate (5 M)
was added and slowly mixed. Propidium iodide (5 M) was then slowly added
to the mixture then was incubated for 15 min in the dark at room temperature.
Diluted Annexin V binding buer was added again then placed on a glass slide
and covered with a glass coverslip after which the cells were observed under a
uorescence microscope (OLYMPUS IX70) using FITC and TRITC channels.
2.7 Cell Cycle Analysis by Flow Cytometry
A ow cytometer is a laser-based instrument that quanties the uorescence
physical characteristics of single cells, which are rst dyed with propidium iodide,
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a DNA binding uorescent dye. As illustrated in Figure 2.1, the single cell sus-
pension passes through a sheath that causes a laminar ow allowing the cells to
individually pass till those cells intersect with an argon-ion laser beam. The ra-
diated light is collected by collection optics to guide the light to dichroic mirrors
(mirrors with dierent properties at 2 dierent wavelengths) and 3 lters for the
purpose of separating dierent wavelength bands. The resulting light signal is
then detected and digitized for computer analysis, transforming the signal into a
histogram [45].
Figure 2.1: Flow Cytometer Schematic. Adapted from Brown & Wittwer, 2000.
Figure was reused with permission from Reference [45], see appendix
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This technology is used for numerous applications, including cell cycle analysis.
The cell cycle (2.2) consists of multiple phases for the division and duplication of
the cell into two daughter cells: G phase (cell growth), S phase (DNA synthesis)
and M phase (mitosis) [46]. Flow cytometry quanties cells in each phase, this
can serve the purpose of identifying in which phase did a particular drug cause
cell cycle arrest in order to further study the genes/proteins or mechanism in
which the drug acts upon.
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Figure 2.2: Cell Cycle Phases. Adapted from Alberts et al, 2002. Figure was
reused with permission from Reference [46], see appendix 8
According to Feng et al (2015), SNU449 cells were seeded in 6 well plates
(Greiner Bio-One, Germany) at 500,000 cells per well and cultured for 24hrs. Cells
were treated with: IC50 of LOR, IC50 of CisPt, and Combination IC50 in FBS-free
media, for 24 hrs with untreated cells as controls. Single cell suspensions were
prepared by trypsinization and re-suspending in PBS or phosphate buered saline,
then were xed with cold 70% ethanol at 4C overnight. Fixed cells were washed
twice with PBS, centrifuged at 500 g for 5 minutes and the supernatant was
discarded. The cells were rst treated with 1mg/ml RNase A (Thermo Scientic,
USA) to get rid of any RNA, then stained with 5 g/ml propidium iodide (Carl
Roth, Germany) for 30 min in the dark at room temperature. [7, 47]. Cells were
analyzed on a COULTER EPICS XL Flow Cytometer (Beckman COULTER,
CA) by the software: Elite XL.
2.8 Statistical Analysis
Experiments were done in triplicates. Data were expressed as mean  stan-
dard deviation. Dierences between treated and untreated control groups were
analyzed by one-way ANOVA followed by Bonferonni's post test using GraphPad
Prism 5.0 software. Statistical signicance was considered at a P-value <0.05(*),
<0.1 (**), and <0.001(***).
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Results
3.1 Cytotoxic Evaluation of LOR and CisPt
individually on HepG2 and SNU449
In order to evaluate the cytotoxic potential of LOR, cell viability assay was
performed by using a range of concentrations of LOR from 0.1 M to 300 M
for 24 hours. As shown in Figure 3.1, LOR has shown a dose dependent eect
on both HepG2 and SNU449. A semi-log plot was graphed by GraphPad Prism
5.0 software for the identication of IC50 of LOR on both cell lines. The IC50 of
HepG2 and SNU449 were calculated to be 55.6 M and 73.2 M, respectively.
A similar plot was graphed to conrm the known eect of CisPt on both HCC
cell lines and to identify the CisPt IC50 of HepG2 and SNU449, using a range of
concentrations of CisPt from 0.1 M to 1000 M for 24 hours. Figure 3.2 shows
and conrms the cytotoxic eect of CisPt on HepG2 and SNU449, with IC50
calculated to be 53.9 M and 116 M for HepG2 and SNU449, respectively.
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Figure 3.1: Cytotoxic eect of LOR on HepG2 and SNU449. Concentration-
viability plots attained after exposure of HepG2 and SNU449 cells
to LOR (0.1 - 300 M) for 24 hrs and the corresponding IC50 for
both cell lines. IC50 values were expressed as mean  standard de-
viation (SD) of three independent experiments, each carried out in 4
replicates (n=4).
Figure 3.2: Cytotoxic eect of CisPt on HepG2 and SNU449. Concentration-
viability plots attained after exposure of HepG2 and SNU449 cells to
CisPt (0.1 - 1000 M) for 24 hrs and the corresponding IC50 for both
cell lines. IC50 values were expressed as mean  standard deviation
(SD) of three independent experiments, each carried out in 4 replicates
(n=4).
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Table 3.1: The Combination Eect of LOR and CisPt on HepG2. Data represents
the mean standard deviation (SD) of three independent experiments,
each carried out in 4 replicates (n=4).
3.2 Combination Eect of LOR and CisPt on
HepG2 and SNU449
To test the potential of LOR to improve chemotherapy, LOR was combined
with CisPt in constant ratios and the eect was tested by cell viability assay on
HCC cell lines. Combination Index (CI) values were calculated using CompuSyn
software (Paramus, NJ), and according to Endo et al (2011), CI>1.3 = antago-
nism; CI 1.1-1.3 = moderate antagonism; CI 0.9-1.1 = additive eect; CI 0.8-0.9
= slight synergism; CI 0.6-0.8 = moderate synergism; CI 0.4-0.6 = synergism; CI
0.2-0.4 = strong synergism.
Tables 3.1 and 3.2 summarizes the drug concentrations used (0.25 X IC50, 0.5
X IC50, IC50, 2 X IC50, 4 X IC50) for each drug, the corresponding cell death
percentage, and the CI value and the corresponding eect of the combination of
each ratio on HepG2 and SNU448, respectively.
For HepG2, the CI values (0.45-0.9) suggested synergistic eects when high
concentrations of both drugs are used (IC50, double and quadruple the IC50) and
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Table 3.2: The Combination Eect of LOR and CisPt on SNU449. Data repre-
sents the mean  standard deviation (SD) of three independent exper-
iments, each carried out in 4 replicates (n=4).
resulted in a higher percentage of inhibition or cell death than each drug alone,
while an antagonistic eect (CI value of 1.65) was shown when low concentrations
of both drugs were used (Table 3.1). As for SNU449, no antagonism was shown
when all 5 ratios were used. CI values of 0.2-0.96 suggested synergistic to additive
eects and resulted in a higher percentage of inhibition or cell death than each
drug alone (Table 3.2).
Combination IC50, which represents the combination of the IC50 of both drugs
combined, was picked for further testing, as it resulted in a high inhibition rate
(83.1 and 73.2% in HepG2 and SNU449, respectively) and has a synergistic and
an additive eect in HepG2 and SNU448, respectively.
3.3 Eect of LOR, CisPt and Combination IC50 on
normal cells
1Br hTERT was used to evaluate the cytotoxicity of LOR, CisPt and combi-
nation of IC50 of both drugs on normal cells. As illustrated in Figure 3.3A, LOR
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was cytotoxic in high concentrations (73.2 M) resulting in 93% cell death, while
upon using lower concentrations (55.6 M), cytotoxicity was lower resulting in
only 25% cell death (Figure 3.3B). CisPt was not cytotoxic neither in low (53.9
M) nor in high (116 M) concentrations, resulting in 20-30% cell death. As for
the combination of the IC50 of both drugs, severe cytotoxicity (94% cell death)
was observed when high concentration ratios of both drugs were used (Figure
3.3A). Lower concentration ratios of both drugs resulted in lower cytotoxicity
(60% cell death) to immortalized skin broblasts (Figure 3.3B).
Figure 3.3: Comparison of cytotoxicity of LOR, CisPt, and Combination on HCC
cell lines and hTERT. (A) Eect of the IC50 of the drugs of SNU449 on
hTERT. (B) Eect of the IC50 of the drugs of HepG2 on hTERT. Data
represents the mean  standard deviation (SD) of two independent
experiments, each carried out in 4 replicates (n=4).
3.4 Apoptosis Analysis on SNU449
Apoptotic assay was done in order to examine if LOR, CisPt and the com-
bination of the IC50 of both drugs, cause cell death via apoptosis or necrosis.
As chemotherapy is the only standard treatment option for advanced HCC pa-
tients, SNU449 cell lines was used as a representitive of advanced HCC stages.
Cells that are positive for annexin V (green uorescence) indicate early apoptosis,
while cells that are positive for PI (red uorescence) indicates necrosis. Cells that
are positive for both stains giving yellow uorescence indicates late apoptosis.
Untreated SNU449 cells (Figure 3.4A) was negative for annexin V (1/58) and
PI staining (1/58) (Figure 3.4B and Table 3.3), indicating that the cells were
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viable. LOR (73.2 M) -treated cells (Figure 3.4C) was positive for annexin V
staining(3/6) but not PI staining (Figure 3.4D and Table 3.3), indicating that
the cells were undergoing early apoptosis. CisPt (116 M) - treated cells (Figure
3.4E) showed increased red uorescence (20/85) than green (2/85) and yellow
(1/85) uorescence (Figure 3.4F and Table 3.3). In addition, CisPt- treated cells
showed change in morphology, where the cells displayed blebs and has a bubbly
appearance (Figure 3.4E), indicating that the cells were undergoing necrosis. As
for cells treated with a combination of 73.2 M LOR and 116 M CisPt (Fig-
ure 3.4G), cells showed red (6/18), green (1/18), and yellow uorescence (2/18),
indicating cells were undergoing necrosis (Figure 3.4H and Table 3.3).
Results 29
Results 30
Results 31
Results 32
Figure 3.4: Annexin V/ PI Staining for Untreated and Treated SNU449 Cells.
Green Fluorescence visualized by the FITC (Fluorescein isothio-
cyanate) Filter indicates early apoptosis, red uorescence visualized
by the TRITC (Tetramethylrhodamine isothiocyanate) lter indicates
necrosis, and yellow uorescence indicates late apoptosis. (A,C,E,G)
represents untreated SNU449 cells, SNU449 cells treated with LOR,
SNU449 cells treated with CisPt, and SNU449 cells treated with a
combination of the IC50 of LOR and CisPt, respectively. (B,D,F,H)
represents merged FITC and TRITC lters for untreated cells, LOR-
treated cells, CisPt-treated cells, and Combination-treated cells.
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Table 3.3: Number of viable cells, cells undergoing early apoptosis, late apopto-
sis, and necrosis for each condition, according to annexin V and PI
staining.
3.5 Cell Cycle Analysis on SNU449
To explore the eect of LOR, CisPt and the combination of the IC50 of LOR
and CisPt on the cell cycle of SNU449 cells, cells were stained with annexin V and
propidium iodide (PI), after which ow cytometry was done. Histograms showed
a statistically signicant decrease in the number of cells in the Go/G1 phase in
CisPt and Combination treated groups compared to control cells (Figure 3.5),
followed by a statistically signicant increase in the G2/M phase in all treated
groups, indicating cell cycle arrest in the G2/M phase.
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Figure 3.5: Eects of LOR, CisPt, and Combination on the cell cycle in SNU449.
(A)Histograms shows the percentage of cells in the phases: sub G1
("F"), Go/G1 ("G"), and G2/M ("Q"/ "P"). (B) Comparision of cells
percentage in the dierent phases upon treatment. (C)Table sum-
marizing Flow cytometry analysis. Data represents the mean (%) 
standard deviation (SD) of two independent experiments. Statistical
comparison were performed by GraphPad Prism 5.0 software using
One-way ANOVA with Bonferonni's post-test. P-value <0.05(*).
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Chapter 4
Discussion and Conclusion
HCC mortality rate is high in the world, especially in Egypt due to the high
incident rates of HBV and HCV [11]. The pathophysiology of HCC is complex
as it is a multifactorial type of cancer. However, common molecular pathways
that are altered in hepatocellular carcinoma includes the WNT/ -catenin, re-
ceptor tyrosine kinase, MAPK, and PI3K-Akt pathways [2], [12]. This makes
HCC a complex and heterogenous event. As most patients are diagnosed in the
advanced stage because of the asymptomatic nature of HCC in its early stages,
chemotherapy is the only standard treatment option [11, 7, 14]. Therefore, ways
to improve chemotherapy is highly required to decrease HCC mortality rate and
increase survival rates.
Antihistamines have been studied for over 15 years in vitro and in vivo and
have shown anticancer potential in some cancer cell lines [27], [7], [6], [28], [5], [48],
[31]. Loratadine, a second generation antihistamine, was thoroughly examined for
its cytotoxic potential against human colon cancer cells (COLO 25) in 2006. LOR
was found to inhibit the proliferation of COLO 25 by inducing cell cycle arrest
in the G2/M phase and by inducing caspase 9 mediated apoptosis [6]. In 2010,
LOR was further studied from another angle by Soule et al. Their hypothesis
was based on the ndings of Chen et al. in 2006: LOR may have an eect on
the radio sensitivity of human colon carcinoma cells due to the nding that LOR
did induce cell cycle arrest in the G2/M phase, which is a radiation sensitive
phase. They concluded that cells pre-treated with LOR did signicantly increase
radiation induction of cytotoxicity and that it directly induces DNA damage in
human colon carcinoma cells [33]. Moreover, Ellegard et al intensively studied the
eect of multiple antihistamines on non-small cell lung cancer (NSCLC) in 2016
and found that LOR not only decreased cancer mortality, but also caused NSCLC
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sensitization to chemotherapy and reverted resistance [35]. Therefore, LOR oers
multiple advantages and showed a potential of being a successful chemotherapetic
agent, a modier of radiation responsiveness in the treatment of cancer, and
caused sensitization to chemotherapy and reverted resistance. This led to the
interest in studying the eect of LOR on certian hepatocellular carcinoma cell
lines to test the potential of LOR to act as a chemotherapeutic agent and to also
test the potential of LOR to improve chemotherapy by studying the eect of the
combination of LOR with CisPt.
Here, the eect of LOR was evaluated, along with its combination with cis-
platin, in HCC cell lines: HepG2 and SNU449, a representative of early stage
and advanced stage of HCC, respectively. Consistent with the results of Chen et
al (2006) on colon cancer cells, COLO 205 cells, LOR showed a dose-dependent
cytotoxicity in both HCC cell lines, with a higher IC50 in SNU449 (73.2 M) than
HepG2 (55.6 M), which may be due to the fact that SNU449 cell line is a more
advanced stage of HCC than HepG2. Therefore, SNU449 was chosen for further
analysis.
Combination therapy is commonly used in chemotherapy for the purpose of de-
creasing the development of resistant cells and to be able to use lower doses to pro-
duce less side eects, which is nephrotoxicity in the case of CisPt [49]. Examples
of using combination therapy includes rituximab and CHOP (cyclophosphamide,
hydroxydaunomycin, Oncovin, and prednisone) chemotherapy for non-Hodgkin's
lymphoma and taxol and Herceptin for breast cancer [50]. Synergism is dened
as a greater net therapeutic eect of the combination of both drugs than the total
sum of eects produced by each drug individually, while additive eect produces
combination therapeutic eect that is equal to the total sum of eects caused by
each drug individually [51]. Antagonism, however, is when the net therapeutic
eect of the combination is less than the sum of eects of each drug alone. Thus,
the optimum drug combination is that which provides additive to synergistic ef-
fects.
In HepG2, the combination of LOR with CisPt produced an antagonistic eect
when used in low concentration ratios (13.9 M LOR:13.5 M CisPt). However,
as higher concentration ratios were used, the combination eects became more
synergestic. In SNU449, no antagonism was produced upon using all combination
ratios, producing additive to synergestic eects. These results indicates that a
greater eect is generated when high concentration ratios of LOR and CisPt
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are used (double and quadruple the IC50 of each drug) than the total eect of
LOR and CisPt alone. This could serve as a great advantage in chemotherapy
as dose-dense chemotherapy is known to improve survival and is used in multiple
cancer types [52]. Therefore, the combination of 55.6 M LOR with 53.9 M
CisPt, resulting in 83% cell death in HepG2, and the combination of 73.2 M
LOR with 116 M CisPt, resulting in 78% cell death in SNU449 were used for
further analysis as both combinations gave synergestic to additive eects with
higher percentage of cell death. Further studies could be needed to inspect the
eect of inconstant ratios, for example, to test the eect of the combination of
low concentrations of CisPt and high concentrations of LOR to further explore
the possibility that LOR can improve chemotherapy eectiveness by decreasing
the nephrotoxicity caused by cisplatin as well as causing optimal cell death.
The IC50 values of LOR, CisPt, and Combination of IC50s of both drugs were
tested against 1 Br hTERT cells. 1 Br hTERT cells are skin broblasts that
are immortalized, which gives them the ability to proliferate in culture. hTERT
was used here as a control/normal cells to give an indication of the cytotoxicity
of the drugs on normal cells. The hypothesis was that LOR will not show any
cytotoxicity as it was clinically tested and was proven to be safe by going through
clinical trials. Unexpectedly, high concentrations of LOR (73.2 M) and high ra-
tios of both drugs(73.2 M LOR and 116 M CisPt) showed severe cytotoxicity to
hTERT (94% cell death), while lower concentrations of LOR (55.6 M) and both
CisPt concentrations (53.9 M and 116 M) didn't exhibit any cytotoxicity.
The cytotoxicity of LOR and its combination with CisPt on hTERT may be
explained by the fact that hTERT shares some cancer-like properties when it
was immortalized, as immortalized cells have increased telomere expression and
could induce tumor growth [53]. Moreover, the study by Chen et al. in 2006
compared concentrations of LOR between 10 - 50 M in humun colon cancer
cells and primary normal cells, but did not evaluate higher concentrations of
LOR in normal cells, even though 75 M of LOR was studied in cancer cells [6].
Consequently, searching for drugs that exhibits higher toxicity on cancer cells
with minimal toxicity on normal cells are attempted. Therefore, further studies
are required to test the eect of the IC50 of LOR and dierent ratios of both
drugs on primary normal hepatocytes.
To elucidate the mechanism by which CisPt and Combination IC50 induced
cell death and inhibited tumor growth, apoptotic assay and cell cycle analysis
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were performed. Apoptotic analysis showed that LOR treated cells were positive
for annexin V staining, which may indicate that LOR induces early apoptosis.
CisPt- treated cells and cells treated with a combination of the IC50 of both drugs
were positive for PT staining, indicating necrosis. However, expression analysis
of markers/genes of apoptosis, such as caspase 8, caspase 9, caspase 3, PARB and
necrotic markets such as HMGB1 or High mobility group protein B1 by real time
PCR and western blotting, as well as TUNEL assay are necessary to conrm the
above result.
Finally, cell cycle analysis was performed to indicate whether treatment with
LOR, CisPt, or combination of the IC50 of both drugs will cause cell cycle ar-
rest. The cell cycle starts with the G1 phase, where cells grow (2N) then cells
begin to replicate in the S phase which is DNA synthesis phase after which cells
continue to grow in the G2 phase and nally divide into 2 daughter cells in the
M phase (4N). A histogram is used to represent the percentage of cells in each
of these stages. The histograms generated in the NSA Diagnostic Labs(Cairo,
Egpyt) showed that treatment with LOR, CisPt and Combination IC50 lead to
an increase in the percentage of cells in the G2/M phase: 22.9%  0.2, 24.5%
 2.9, and 24.6%  1.6, respectively, compared to the untreated SNU449 cells,
14.4%  0.00, which is an indication that cells are accumulated in the G2/M
phase and could not complete the cell cycle. Moreover, there was a decrease
in the percentage of cells in the Go/G1 phase: 68.8%  0.1, 65.3%  3.6, and
65.8%  0.57, respectively, compared to the untreated SNU449 cells, 74.2% 
0.14, which conrms the hypothesis of the cell cycle arrest in the G2/M phase,
as cells were not able to complete the cycle and therefore the percentage of cells
decreased in the following phase, which is Go/G1. Consistent with other studies
[6], [33], LOR-treated colon cancer cells also resulted in cell cycle arrest in the
G2/M phase.
In conclusion, the ndings displayed in this thesis signies the anticancer po-
tential of loratadine in 2 HCC cell lines: HepG2 and SNU449. As LOR is already
reported to be a released antihistamine that is prescribed to children and adults,
this had driven further interest to explore its capacity to improve chemother-
apy. Cisplatin in combination with LOR resulted in synergistic to additive eects
when the IC50 of both drugs were used and resulted in higher percentage of cell
death. This can open doors to investigate the possibility of evaluating the use of
anthistamines in cancer in vivo and even clinically.
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Future Directions
1. Investigate the anticancer potential of LOR on Huh7 cell line(HCC cell line
derived from HCV) could shed light on its eect on HCC derived from HCV,
which represents most of the cases in Egypt.
2. Investigate the eect of inconstant concentration ratios of LOR and CisPt,
i.e. low concentration of CisPt in combination with high concentration of
LOR, on HCC cell lines.
3. Investigate the eect of LOR in combination with sorafenib could give a
clearer indication of the potential of LOR to improve chemotherapy, as
sorafenib is used in chemotherapy for advanced HCC.
4. In order to elucidate the mechanism in which LOR and the combination
of loratadine and chemotherapeutic drugs, RNA sequencing would be very
benecial to examine the eect of the therapy on the transcriptome level in
order to identify all the genes and pathways that got deregulated by such
therapy.
5. More studies are required to test the eect of higher concentrations of LOR
(>50 M) on primary normal cells.
6. More In vitro studies, such as expression analysis of apoptotic markers
and cell regulatory genes are necessary to conrm the eect of LOR and
combination therapy on HCC cell lines and to examine the method of action
of LOR and its combination with cisplatin.
7. In vivo studies are necessary to conrm the eect of LOR and combination
therapy on animal models.
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